Video Insights
Video Insights
Advertisement
Neal Shore, MD, FACSLocalized | June 13, 2024
Dr. Shore discusses treatment-related adverse events associated with apalutamide and ADT.
View More
Neal Shore, MD, FACSLocalized | June 13, 2024
Dr. Shore discusses the effects of apalutamide plus ADT in patients with prostate cancer.
Pedro Barata, MDCRPC | June 13, 2024
Dr. Pedro Barata discusses his research letter examining patterns of HRR mutation genetic testing in men with mCRPC.
Ovidio Fernandez Calvo, MDMuscle Invasive Urothelial Carcinoma | June 13, 2024
Dr. Calvo offers insights on an interim analysis of the atezobladderpreserve phase 2 clinical trial in MIBC.
Anthony M. Joshua, MBBS, PhD, FRACPLocalized | June 13, 2024
Drs. Joshua and Wallis contextualize the Metformin Active Surveillance Trial for management of low-risk prostate cancer.
Karine Tawagi, MDAdvancements in Oncology | June 12, 2024
Dr. Tawagi considers how "favorable" and "very favorable" risk alters her approach to patient management for aRCC.
Karine Tawagi, MDAdvancements in Oncology | June 12, 2024
Dr. Tawagi opines on whether the high rates of crossover in the PSMAfore control arm limit the applicability of the results.
Karine Tawagi, MDAdvancements in Oncology | June 13, 2024
Dr. Tawagi provides an update as to when SG or chemotherapy should be preferred for patients who do not respond to EV/pembro.
Karine Tawagi, MDAdvancements in Oncology | June 13, 2024
Dr. Tawagi describes how she is using ctDNA in her practice in the EV/pembro setting, and how frequently she is ordering it.
Karine Tawagi, MDAdvancements in Oncology | June 13, 2024
Dr. Tawagi explains the treatment options available for patients with metastatic bladder cancer who already have neuropathy.
Alicia Morgans, MD, MPHCRPC | June 12, 2024
Drs. Morgans, Wallis dissect the association between PSA level of < 0.2 ng/mL and risk of radiological progression in ...
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | June 12, 2024
Dr. Grivas offers long-term outcomes from the JAVELIN Bladder 100 study pertaining to specific patient populations.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | June 12, 2024
Dr. Grivas provides an update on relevant clinical trial updates and data readouts pertaining to urothelial carcinoma.
Andrea B. Apolo, MDTesticular, Penile, and Rare Malignancies | June 12, 2024
Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.
Karine Tawagi, MDAdvancements in Oncology | June 13, 2024
Dr. Tawagi shares how she counsels patients with metastatic UC, including whether she always recommends EV/pembro.
Benjamin H. LowentrittASCO 2024 | June 10, 2024
Dr. Lowentritt sheds light on a real-world comparison of PSA response in patients with mCSPC treated with apalutamide.
Vitaly Margulis, MDUpper Tract Urothelial Carcinoma | June 10, 2024
Drs. Margulis and Murray showcase the ENLIGHTED study examining the efficacy and safety of padeliporfin VTP for LG UTUC.
Tian Zhang, MDProstate Cancer Diagnostics | June 10, 2024
Dr. Zhang expands on treatment outcomes for patients with prostate cancer after imaging with Ga68-PSMA-PET.
Tian Zhang, MDAdvanced Renal Cell Carcinoma | June 10, 2024
Dr. Zhang highlights the results of a phase 2 trial for sequential treatment of cabozantinib in advanced RCC.
Laurence Albiges, MD, PhDnccRCC | June 10, 2024
Dr. Albiges comments on the latest data from the nccRCC trial KEYNOTE-B61, including an extended follow-up analysis.
Advertisement
Advertisement
Advertisement